Axsome Therapeutics, Inc.
AXSMNASDAQHealthcare● Active
$237.85
+$5.53(+2.38%)
Market Cap$12.2B
P/E Ratio—
52W High$242.41
52W Low$96.09
Axsome Therapeutics, Inc. (AXSM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AXSM · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.64B | $0.39B | $0.27B | $0.05B | $0.00B |
| Cost of Revenue | $0.05B | $0.03B | $0.03B | $0.01B | $0.00B |
| Gross Profit | $0.59B | $0.35B | $0.24B | $0.04B | $0.00B |
| Gross Margin %(computed) | 92.56% | 91.37% | 90.37% | 89.61% | — |
| Operating Expenses | |||||
| R&D Expenses | $0.18B | $0.19B | $0.10B | $0.06B | $0.06B |
| G&A Expenses | $0.00B | $0.31B | $0.22B | $0.00B | $0.07B |
| Total Operating Expenses | $0.76B | $0.63B | $0.48B | $0.22B | $0.12B |
| Operating Income | ($0.17B) | ($0.28B) | ($0.23B) | ($0.18B) | ($0.12B) |
| Operating Margin %(computed) | -26.51% | -72.74% | -85.67% | -359.33% | — |
| Interest Income | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.01B | $0.01B | $0.01B | $0.01B | $0.01B |
| Income Before Tax | ($0.18B) | ($0.29B) | ($0.24B) | ($0.19B) | ($0.13B) |
| Income Tax Expense | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.18B) | ($0.29B) | ($0.24B) | ($0.19B) | ($0.13B) |
| Net Margin %(computed) | -28.69% | -74.47% | -88.41% | -373.99% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.04B | 0.04B |
| EBITDA | ($0.17B) | ($0.27B) | ($0.22B) | ($0.18B) | ($0.12B) |
| EBITDA Margin %(computed) | -26.32% | -70.68% | -83.15% | -350.53% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Axsome Therapeutics, Inc. data
About Axsome Therapeutics, Inc. (AXSM) Income Statement
Axsome Therapeutics, Inc. (AXSM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AXSM reported revenue of $0.64B, gross profit of $0.59B (gross margin 92.56%), and net income of ($0.18B) — a net profit margin of -28.69%.
Frequently asked questions
AXSM · 4 questionsAxsome Therapeutics, Inc. (AXSM) reported revenue of $0.64B for 2025, up 65.5% year-over-year.
AXSM revenueAXSM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08